Boehringer Ingelheim Joins Responsible Health Initiative
The initiative’s fourth member expands sustainability collaboration across the global health supply chain
Paris and New York – (December 12, 2019) — The Responsible Health Initiative (RHI), a collaborative industry partnership focused on boosting sustainability across the pharmaceutical and healthcare supply chain, announced that Boehringer Ingelheim has joined its partnership. Boehringer Ingelheim is the fourth member to join the initiative, which is powered by EcoVadis, the world leader in business sustainability intelligence and ratings for global supply chains.
Boehringer Ingelheim will collaborate with RHI members GlaxoSmithKline, Teva Pharmaceutical Industries Ltd. and Takeda to improve the social, ethical and environmental impact within their supply chains.
RHI will enable Boehringer Ingelheim to identify high-performing suppliers and best practices, reduce operational disruptions, mitigate risk, and drive more value with suppliers. Their current and future assessed suppliers can opt-in to the pool of over 1,300 shared scorecards, which provides visibility across RHI members.
“Boehringer Ingelheim joining RHI is a healthy sign that the momentum for industry-specific sustainable procurement collaboration is increasing,” said Pierre-Francois Thaler, Co-CEO and Co-Founder of EcoVadis. “Collaboration leads to stronger performance, increased visibility and better sustainability and supply chain outcomes. We look forward to seeing the benefits multiply as this initiative continues to expand.”
The vision of RHI is to create synergies across the healthcare and pharmaceutical sector to raise standards and improve sustainability and CSR.
Antitrust compliance statement: The members of RHI are committed to conducting all its activities in compliance with the antitrust and competition laws of all applicable countries. Members agree at all interactions they shall not enter into any discussion, activity or conduct that may infringe, on its part or on the part of its members, any applicable competition law.
About Responsible Health Initiative
The Responsible Health Initiative (RHI) was founded in 2018 by leading companies within the industry, in an effort to accelerate RHI members’ efforts in boosting sustainability in their value chains, while creating benefits for their trading partners. Members include GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, and Boehringer Ingelheim. RHI has adopted a proven model of industry collaboration that leverages sharing of best practices and processes, drives a common understanding across the industry, and uses common tools to create efficiencies that improve sustainability performance across its members’ collective supply chains. Learn more at responsiblehealthinitiative.com, and sign up for the pharmaceutical industry’s sustainable supply chain newsletter here.
About Boehringer Ingelheim[1]
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure, amounting to nearly 3.2 billion euros, corresponded to 18.1 percent of net sales. As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment. More information about Boehringer Ingelheim can be found on boehringer-ingelheim.com.
About EcoVadis
EcoVadis offers the world’s most trusted and widely accepted business sustainability ratings for global supply chains. More than 55,000 businesses and six leading sector initiatives are part of the EcoVadis network, all working together with a single methodology, scoring system and platform to evaluate and improve sustainability performance. Backed by powerful technology and a global team of CSR experts, EcoVadis’ easy-to-use and actionable sustainability scorecards provide detailed insight into environmental, social and ethical risks across 190 purchasing categories and 150 countries. The scores equip organizations with the intelligence they need to protect their brands, accelerate growth and drive performance. Learn more on ecovadis.com, Twitter or LinkedIn.
Media contacts
US: Abigail Holmes
ecovadis@corporateink.com
+1 678-977-7962
Europe: David McClintock
dmcclintock@ecovadis.com
+33 1 82 83 86 09
About the Author
Follow on Twitter Follow on Linkedin Visit Website More Content by EcoVadis EN
